## Peter J Mogayzel Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8081333/publications.pdf

Version: 2024-02-01

71 papers 3,908 citations

236925 25 h-index 62 g-index

73 all docs

73 docs citations

times ranked

73

3614 citing authors

#	Article	IF	CITATIONS
1	Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. Journal of Cystic Fibrosis, 2022, 21, 143-145.	0.7	12
2	Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 463-466.	0.5	7
3	Characterizing mucociliary clearance in young children with cystic fibrosis. Pediatric Research, 2021,	2.3	1
4	Vaping-related Lung Injury in an Adolescent. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 481-482.	5.6	9
5	Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. JAMA Network Open, 2020, 3, e201737.	5.9	102
6	Curbing Youth E-cigarette Use Must Remain a Priority. Pediatrics, 2020, 146, e20200902.	2.1	2
7	Changes in mucociliary clearance over time in children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 2307-2314.	2.0	6
8	A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis, 2020, 19, 546-552.	0.7	17
9	Ivacaftor for the treatment of cystic fibrosis in children under six years of age. Expert Review of Respiratory Medicine, 2020, 14, 547-557.	2.5	6
10	Real World Experience of Pseudomonas aeruginosa Eradication at an Urban Pediatric Cystic Fibrosis Center. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 623-628.	0.5	1
11	Maintenance of Pulmonary Therapies. Respiratory Medicine, 2020, , 199-213.	0.1	O
12	Appetitive characteristics in children with cystic fibrosis: Questionnaire validation and associations with nutritional status. Appetite, 2019, 139, 90-94.	3.7	3
13	Cystic fibrosis in the era of precision medicine. Paediatric Respiratory Reviews, 2018, 25, 64-72.	1.8	23
14	Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 204-211.	1.4	5
15	Use of the Modified Shuttle Walk Test During Inpatient Pediatric Cystic Fibrosis Pulmonary Exacerbation Treatment. Journal of Acute Care Physical Therapy, 2018, 9, 136-142.	0.2	O
16	Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight, 2018, 3, .	5.0	56
17	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1144-1151.	5.6	96
18	Asthma Screening in Pediatric Sickle Cell Disease: A Clinic-Based Program Using Questionnaires and Spirometry. Pediatric, Allergy, Immunology, and Pulmonology, 2017, 30, 232-238.	0.8	7

#	Article	IF	Citations
19	The Association Between Pain and Clinical Outcomes in Adolescents With Cystic Fibrosis. Journal of Pain and Symptom Management, 2016, 52, 681-687.	1.2	22
20	Transitions in Health Care. Pediatric Clinics of North America, 2016, 63, 887-897.	1.8	19
21	Web-Based Intervention for Nutritional Management in Cystic Fibrosis: Development, Usability, and Pilot Trial. Journal of Pediatric Psychology, 2016, 41, 510-521.	2.1	9
22	Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis inÂChineseÂChildren. Journal of Pediatrics, 2016, 171, 269-276.e1.	1.8	34
23	Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial $\langle i \rangle$ Pseudomonas aeruginosa $\langle i \rangle$ Infection. Annals of the American Thoracic Society, 2014, 11, 1640-1650.	3.2	197
24	Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Quality and Safety, 2014, 23, i3-i8.	3.7	64
25	Mucus Removal Is Impaired in Children with Cystic Fibrosis Who Have Been Infected by Pseudomonas aeruginosa. Journal of Pediatrics, 2014, 164, 839-845.	1.8	12
26	ESCF Care Guidelines beyond Europe. Journal of Cystic Fibrosis, 2014, 13, 359-360.	0.7	0
27	Environmental allergies and respiratory morbidities in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 857-864.	2.0	7
28	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 680-689.	5.6	554
29	Multisite Comparison of Mucociliary and Cough Clearance Measures Using Standardized Methods. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 157-164.	1.4	47
30	Exercise improves lung function and habitual activity in children with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 18-23.	0.7	46
31	Nutritional outcomes following gastrostomy in children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 743-748.	2.0	37
32	A Pilot Study to Examine the Effect of Chronic Treatment with Immunosuppressive Drugs on Mucociliary Clearance in a Vagotomized Murine Model. PLoS ONE, 2012, 7, e45312.	2.5	12
33	Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening. Clinica Chimica Acta, 2011, 412, 1376-1381.	1.1	8
34	Totally Implantable Vascular Access Devices in Adult Patients for Cystic Fibrosis Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 134-135.	<b>5.</b> 6	1
35	Pain Is a Common Problem Affecting Clinical Outcomes in Adults With Cystic Fibrosis. Chest, 2011, 140, 1598-1603.	0.8	46
36	Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulmonary Medicine, 2011, 11, 45.	2.0	24

#	Article	IF	Citations
37	Update in Cystic Fibrosis 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1620-1624.	<b>5.</b> 6	17
38	Lung Function and Late Pulmonary Complications Among Survivors of Hematopoietic Stem Cell Transplantation During Childhood. Paediatric Respiratory Reviews, 2010, 11, 115-122.	1.8	30
39	Early Eradication of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. Paediatric Respiratory Reviews, 2010, 11, 177-184.	1.8	79
40	Description of a Standardized Nutrition Classification Plan and its Relation to Nutritional Outcomes in Children with Cystic Fibrosis. Journal of Pediatric Psychology, 2010, 35, 6-13.	2.1	21
41	False Negative Cystic Fibrosis Newborn Screen. Clinical Pediatrics, 2010, 49, 214-216.	0.8	11
42	Location and Duration of Treatment of Cystic Fibrosis Respiratory Exacerbations Do Not Affect Outcomes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1137-1143.	5.6	91
43	Update in Cystic Fibrosis 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 539-544.	<b>5.</b> 6	34
44	Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis, 2010, 9, 143-149.	0.7	28
45	Vagal control of mucociliary clearance in murine lungs: A study in a chronic preparation. Autonomic Neuroscience: Basic and Clinical, 2010, 154, 74-78.	2.8	11
46	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 298-306.	5.6	225
47	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 802-808.	<b>5.</b> 6	634
48	Spontaneous resolution of diffuse persistent pulmonary interstitial emphysema. Pediatric Pulmonology, 2008, 43, 615-619.	2.0	27
49	Increased Mortality After Pulmonary Fungal Infection Within the First Year After Pediatric Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 655-661.	0.6	62
50	Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjects. Pulmonary Pharmacology and Therapeutics, 2008, 21, 105-111.	2.6	1
51	Dietary supplement use in pediatric patients with cystic fibrosis. American Journal of Health-System Pharmacy, 2008, 65, 562-565.	1.0	5
52	Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent. Pediatric Nursing, 2008, 34, 464-8; quiz 468-9.	0.5	10
53	Albuterol Improves Impaired Mucociliary Clearance After Lung Transplantation. Journal of Heart and Lung Transplantation, 2007, 26, 138-144.	0.6	24
54	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 957-969.	5.6	773

#	Article	IF	CITATIONS
55	Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: Non-infectious and long-term complications. Pediatric Blood and Cancer, 2007, 49, 225-233.	1.5	43
56	Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: Overview, diagnostic considerations, and infectious complications. Pediatric Blood and Cancer, 2007, 49, 117-126.	1.5	34
57	Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs. Pediatric Transplantation, 2003, 7, 469-473.	1.0	34
58	Effect of Adeno-Associated Virus–Specific Immunoglobulin G in Human Amniotic Fluid on Gene Transfer. Human Gene Therapy, 2003, 14, 365-373.	2.7	8
59	Ciprofloxacin-induced renal insufficiency in cystic fibrosis. Journal of Cystic Fibrosis, 2003, 2, 152-154.	0.7	16
60	Modulation of Sp1 and Sp3 in Lung Epithelial Cells Regulates ClC-2 Chloride Channel Expression. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 499-505.	2.9	13
61	Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient. Progress in Transplantation, 2003, 13, 61-64.	0.7	3
62	Cyclosporin and tacrolimus do not potentiate oxidative damage in pulmonary epithelial cells. Transplant International, 2003, 16, 709-712.	1.6	0
63	Bilateral diaphragm paralysis following lung transplantation and cardiac surgery in a 17-year-old. Journal of Heart and Lung Transplantation, 2002, 21, 710-712.	0.6	11
64	cis-Acting elements within CFTR 5′-flanking DNA are not sufficient to decrease gene expression in response to phorbol ester. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1576, 306-315.	2.4	0
65	Eosinophilic infiltrates in a pulmonary allograft: a case and review of the literature. Journal of Heart and Lung Transplantation, 2001, 20, 692-695.	0.6	13
66	An unusual case of fatal pulmonary allograft rejection. Pediatric Transplantation, 2001, 5, 138-141.	1.0	2
67	CFTR Intron 1 Increases Luciferase Expression Driven by CFTR 5′-Flanking DNA in a Yeast Artificial Chromosome. Genomics, 2000, 64, 211-215.	2.9	15
68	Sleep-disordered breathing in children with achondroplasia. Journal of Pediatrics, 1998, 132, 667-671.	1.8	90
69	Elastase effect on the extracellular matrix of rat aortic smooth muscle cells in culture. Experimental and Molecular Pathology, 1986, 45, 105-117.	2.1	16
70	A micromethod for the purification of lysyl oxidase. Analytical Biochemistry, 1982, 126, 312-317.	2.4	3
71	Rapid Quantitation of desmosine content in tissue hydrolysates by high-performance liquid chromatography. Analytical Biochemistry, 1981, 114, 71-74.	2.4	21